SPY328.79+2.27 0.70%
DIA266.72+2.37 0.90%
IXIC10,902.80+157.52 1.47%

Plus Therapeutics shares are trading higher after the company reported the completion of the fifth dose-escalation cohort of its ReSPECT Glioblastoma trial.

Benzinga · -